Iovance Biotherapeutics, Inc. – NASDAQ:IOVA

Add to watchlist

$2.61

-4.76

-64.59%

Market closed

Open in about 9 hours

-15.58%

month

-15.58%

quarter

+1.94%

year

Market Cap	2.27B
Enterprise value	N/A

P/E	-2.34
EV/Sales	N/A
EV/EBITDA	N/A
Price/Sales	N/A
Price/Book	1.81
PEG ratio	0.20
EPS	-1.8

Revenue	1.90M
EBITDA	-447.80M
Income	-449.64M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	-23519.12%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Iovance Biotherapeutics Stock Forecast

M Q Y

Last Year

$21.33

Potential upside: 717.36%

Analysts Price target
Financials & Ratios estimates

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA): Profit margin
Jun 2023	238K	-106.52M	-44759.66%
Sep 2023	469K	-113.76M	-24255.86%
Dec 2023	482K	-116.37M	-24145.02%
Mar 2024	715K	-112.97M	-15800.84%

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA): Debt to assets
Jun 2023	757293000	178.72M	23.6%
Sep 2023	852315000	178.30M	20.92%
Dec 2023	780351000	195.73M	25.08%
Mar 2024	869830000	189.80M	21.82%

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA): Cash Flow
Jun 2023	-93.95M	-156.77M	1.02M
Sep 2023	-84.08M	-79.01M	202.8M
Dec 2023	-83.97M	-72.84M	962K
Mar 2024	-122.27M	-111.50M	193.57M

Iovance Biotherapeutics alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Iovance Biotherapeutics
Employees

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA): Employee count
Aug 2023	503
Sep 2023	503
Oct 2023	503
Nov 2023	503
Dec 2023	503
Jan 2024	503
Feb 2024	503
Mar 2024	557
Apr 2024	557
May 2024	557
Jun 2024	557
Jul 2024	557

Iovance Biotherapeutics
Hedge Funds Holdings Q1 2022

100.00% 0.00%

of IOVA is owned by hedge funds

237 +0

hedge funds hold IOVA stock

154.34M -1.46M

shares is hold by hedge funds

IOVA hedge funds holdings changes

Iovance Biotherapeutics
Insider Trading

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA): Insider trades (number of shares)
Period	Buy	Sel
Feb 2024	5282000	0
Nov 2024	0	50000

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Option	16 Dec 2024	PURI RAJ K. officer: Chief Regulatory Officer officer: Chief Regulatory Officer	Restricted Stock Units	8,334	N/A	N/A
Option	16 Dec 2024	PURI RAJ K. officer: Chief Regulatory Officer officer: Chief Regulatory Officer	Common Stock	8,334	N/A	N/A
Option	2 Dec 2024	VOGT FREDERICK G director, officer..	Common Stock	10,417	N/A	N/A
Option	2 Dec 2024	VOGT FREDERICK G director, officer..	Common Stock	10,417	N/A	N/A
Option	2 Dec 2024	VOGT FREDERICK G director, officer..	Restricted Stock Units	10,417	N/A	N/A
Option	2 Dec 2024	VOGT FREDERICK G director, officer..	Restricted Stock Units	10,417	N/A	N/A
Option	2 Dec 2024	BILINSKY IGOR officer: Chief Operating Officer officer: Chief Operating Officer	Common Stock	3,516	N/A	N/A
Option	2 Dec 2024	BILINSKY IGOR officer: Chief Operating Officer officer: Chief Operating Officer	Restricted Stock Units	3,516	N/A	N/A
Option	2 Dec 2024	GRAF FINCKENSTEIN FRIEDRICH officer: Chief Me..	Common Stock	3,906	N/A	N/A
Option	2 Dec 2024	GRAF FINCKENSTEIN FRIEDRICH officer: Chief Me..	Common Stock	3,906	N/A	N/A

IOVA insider trading transactions

Iovance Biotherapeutics
Earnings Call Transcripts

Quarter	Transcript
Q1 2024 9 May 2024	Q1 2024 Earnings Call Transcript
Q4 2023 28 Feb 2024	Q4 2023 Earnings Call Transcript
Q3 2023 7 Nov 2023	Q3 2023 Earnings Call Transcript
Q2 2023 8 Aug 2023	Q2 2023 Earnings Call Transcript

IOVA earnings call transcripts

Iovance Biotherapeutics
Executives

Insider	Age	Compensation
Mr. Jean-Marc Bellemin M.B.A. (1972) Chief Financial Officer & Principal Accounting Officer	53	$580,000
Dr. Friedrich Graf Finckenstein M.D. (1967) Chief Medical Officer	58	$551,400
Dr. Frederick G. Vogt Ph.D., Esq. (1974) Interim Pres, Chief Executive Officer, Gen. Counsel & Corporation Sec.	51	$515,400

Iovance Biotherapeutics
Latest News

Friday, 20 December 2024
17:00	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)	globenewswire.com
Thursday, 19 December 2024
04:02	If I Could Only Buy 3 Stocks in the Last Month of 2024, I'd Pick These	fool.com
Tuesday, 17 December 2024
05:29	2 Growth Stocks That Could Rocket Higher in 2025: Are They Right for Your Portfolio?	fool.com
Thursday, 12 December 2024
10:00	Prediction: This Stock Will Beat the Market in 2025	fool.com
Saturday, 7 December 2024
11:08	3 Monster Stocks to Hold for the Next 10 Years	fool.com
Wednesday, 27 November 2024
06:30	Is Iovance Biotherapeutics Stock a Millionaire Maker?	fool.com
Tuesday, 26 November 2024
16:01	Iovance Biotherapeutics Announces the Promotion of Raj Puri, M.D., Ph.D. to Chief Regulatory Officer	globenewswire.com
Saturday, 23 November 2024
11:35	Got $1,500? Buy Iovance Biotherapeutics Now and Don't Look Back	fool.com
Friday, 22 November 2024
10:00	2 Innovative Stocks That Could Deliver Outsize Returns	fool.com
Saturday, 16 November 2024
06:00	2 Top Biotech Stocks to Buy Now and Hold For 5 Years or More	fool.com
Monday, 11 November 2024
14:16	Iovance Biotherapeutics Q3: A Beat, But A Selloff - Now A Buy Opportunity	seekingalpha.com
Friday, 8 November 2024
11:15	IOVA Posts Narrower-Than-Expected Q3 Loss, Amtagvi Sales Drive Top line	zacks.com
Thursday, 7 November 2024
20:55	Iovance Biotherapeutics, Inc. (IOVA) Q3 2024 Earnings Call Transcript	seekingalpha.com
18:46	Iovance Biotherapeutics (IOVA) Reports Q3 Loss, Tops Revenue Estimates	zacks.com
16:01	Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Third Quarter and Year to Date 2024	globenewswire.com
Thursday, 31 October 2024
16:01	Iovance Biotherapeutics to Host Third Quarter and Year-to-Date 2024 Financial Results Conference Call and Webcast on Thursday, November 7, 2024	globenewswire.com
Thursday, 24 October 2024
18:01	Why Iovance Biotherapeutics Stock Triumphed on Thursday	fool.com
Friday, 4 October 2024
08:30	Is Iovance Biotherapeutics Stock a Buy?	fool.com
Thursday, 3 October 2024
14:43	Iovance Biotherapeutics: Moving To The Next Phase	seekingalpha.com
Thursday, 26 September 2024
08:15	3 Reasons to Buy Iovance Biotherapeutics Stock Like There's No Tomorrow	fool.com
Monday, 16 September 2024
06:29	3 Things You Need to Know if You Buy Iovance Biotherapeutics Today	fool.com
Friday, 6 September 2024
09:30	This Is the Biggest Risk With Iovance Biotherapeutics Stock	fool.com
Tuesday, 3 September 2024
17:00	Iovance Biotherapeutics to Present at Upcoming Conferences	globenewswire.com
Monday, 2 September 2024
18:15	3 Monster Biotech Stocks to Buy Before 2025	fool.com
Tuesday, 27 August 2024
04:36	Up 47% in 2024: Where Will Iovance Biotherapeutics Be in 5 Years?	fool.com
Friday, 16 August 2024
17:00	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)	globenewswire.com
Wednesday, 14 August 2024
07:15	This 1 Big Risk Is Also 1 Big Opportunity for Iovance Biotherapeutics Stock	fool.com
Sunday, 11 August 2024
09:00	Iovance's Tumor-Fighting TILs Are Just Warming Up (Rating Upgrade)	seekingalpha.com
Friday, 9 August 2024
12:23	Why Iovance Biotherapeutics Shares Are Soaring Today	fool.com
12:20	Why Is Iovance Bio (IOVA) Stock Up 18% Today?	investorplace.com

Frequently Asked Questions (FAQ)

What's the price of Iovance Biotherapeutics stock today?

One share of Iovance Biotherapeutics stock can currently be purchased for approximately $2.61.
When is Iovance Biotherapeutics's next earnings date?

Unfortunately, Iovance Biotherapeutics's (IOVA) next earnings date is currently unknown.
Does Iovance Biotherapeutics pay dividends?

No, Iovance Biotherapeutics does not pay dividends.
How much money does Iovance Biotherapeutics make?

Iovance Biotherapeutics has a market capitalization of 2.27B.
What is Iovance Biotherapeutics's stock symbol?

Iovance Biotherapeutics, Inc. is traded on the NASDAQ under the ticker symbol "IOVA".
What is Iovance Biotherapeutics's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Iovance Biotherapeutics?

Shares of Iovance Biotherapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Iovance Biotherapeutics's key executives?
Iovance Biotherapeutics's management team includes the following people:
- Mr. Jean-Marc Bellemin M.B.A. Chief Financial Officer & Principal Accounting Officer(age: 53, pay: $580,000)
- Dr. Friedrich Graf Finckenstein M.D. Chief Medical Officer(age: 58, pay: $551,400)
- Dr. Frederick G. Vogt Ph.D., Esq. Interim Pres, Chief Executive Officer, Gen. Counsel & Corporation Sec.(age: 51, pay: $515,400)
How many employees does Iovance Biotherapeutics have?

As Jul 2024, Iovance Biotherapeutics employs 557 workers.
When Iovance Biotherapeutics went public?

Iovance Biotherapeutics, Inc. is publicly traded company for more then 14 years since IPO on 15 Oct 2010.
What is Iovance Biotherapeutics's official website?

The official website for Iovance Biotherapeutics is iovance.com.
Where are Iovance Biotherapeutics's headquarters?

Iovance Biotherapeutics is headquartered at 825 Industrial Road, San Carlos, CA.
How can i contact Iovance Biotherapeutics?

Iovance Biotherapeutics's mailing address is 825 Industrial Road, San Carlos, CA and company can be reached via phone at +65 02607120.
What is Iovance Biotherapeutics stock forecast & price target?

Based on 3 Wall Street analysts` predicted price targets for Iovance Biotherapeutics in the last 12 months, the avarage price target is $21.33. The average price target represents a 717.36% change from the last price of $2.61.

Iovance Biotherapeutics, Inc.

iovance.com

Exchange:

NASDAQ

Full time employees:

557

Industry:

Biotechnology

Sector:

Healthcare

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

+65 02607120

825 Industrial Road
San Carlos, CA 94070

CIK: 0001425205
ISIN: US4622601007
CUSIP: 462260100